EX-FILING FEES 2 ibrx20221212s-3mefex107.htm EX-FILING FEES Document
EXHIBIT 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
ImmunityBio, Inc.
(Exact Name of Registrant as Specified in its Charter)
Newly Registered Securities
Security
Type
Security
Class
Title
Fee
Calculation
Rule
Amount
Registered
Proposed
Maximum
Offering
Price
Per
Share
Maximum
Aggregate
Offering
Price
Fee
Rate
Amount of
Registration
Fee
Equity
Common
Stock, par
value
$0.0001
per share
Rule 457(o)
(1)(1)(1)
EquityWarrantsRule 457(o)(1)(1)(1)
Unallocated (Universal) ShelfUnallocated (Universal) ShelfRule 457(o)(1)(1)$18,400,000 
$110.20 per
$1,000,000
$2,027.68 
Total Offering Amounts$18,400,000 $2,027.68 
Total Fees Paid Previously— 
Total Fee Offsets— 
Net Fee Due$2,027.68 
_______________
(1)The Registrant previously registered the offer and sale of certain securities, including its common stock, par value $0.0001 per share, and warrants to purchase shares of common stock, having a proposed maximum aggregate offering price of $500,000,000 pursuant to Registration Statement on Form S-3ASR (File No. 333-255699) which was filed on April 30, 2021 and became automatically effective (the “Original Registration Statement”). The Registrant also filed Post-Effective Amendment No. 3 to Registration Statement on Form S-3 (File No. 333-255699) (the “Prior Registration Statement”), which was filed on May 16, 2022 and declared effective by the Securities and Exchange Commission on May 18, 2022. As of the date hereof, a balance of $92,000,000 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the Registrant is hereby registering the offer and sale of an additional $18,400,000 of its shares of common stock, warrants to purchase shares of common stock and the shares of common stock issuable upon the exercise of such warrants. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement.